白细胞介素-33在过敏性哮喘小鼠体内的变化及作用

摘要/Abstract

摘要：

目的探讨白细胞介素-33（IL-33）在粉尘螨1类变应原（Der f 1）诱导的过敏性哮喘小鼠中的变化及作用。方法将40只雌性BALB/c小鼠用随机数字表法分为哮喘组、免疫治疗组、抑制剂组和阴性对照组（PBS组）,每组10只。哮喘组、免疫治疗组和抑制剂组分别在第0、7和14天腹腔注射100 μl粉尘螨变应原提取液（含100 μg/ml Der f 1）,抑制剂组小鼠同时注射抑制剂（可溶性ST2 100 μl,用于抑制IL-33）,PBS组注射等量PBS。第21天起,各组小鼠雾化吸入粉尘螨变应原提取液（0.5 μg/ml）,30 min/次,1次/d,连续7 d。免疫治疗组小鼠第25天起于雾化前0.5 h,分别用200 μl的Der f 1蛋白溶液（100 μg/ml）腹腔注射进行免疫治疗,PBS组用PBS代替粉尘螨变应原。第27天雾化吸入后24 h处死小鼠,收集小鼠支气管肺泡灌洗液（BALF）和眼球血,并对BALF中嗜酸粒细胞进行计数,制作肺组织病理切片。ELISA法检测BALF中IL-5、IL-13和γ干扰素（IFN-γ）的含量及血清中特异性IgE和IgG2a水平。结果除PBS组小鼠外,其他组小鼠自第21天开始出现不同程度的哮喘症状。自第25天开始,免疫治疗组小鼠的哮喘症状开始缓解。哮喘组和PBS组小鼠BALF中嗜酸粒细胞总数分别为(4.41 ± 0.36） × 10⁵/ml和（0.37 ± 0.08） × 10⁵/ml,两组差异有统计学意义（t = 24.50,P < 0.01）;免疫治疗组和抑制剂组小鼠的嗜酸粒细胞总数分别为（1.43 ± 0.14） × 10⁵/ml和(2.73 ± 0.33）× 10⁵/ml,均明显低于哮喘组（F = 129.72,P < 0.01）。ELISA检测结果显示,哮喘组、免疫治疗组、抑制剂组和PBS组BALF中IFN-γ的水平分别为（83.06 ± 11.38）、（277.97 ± 22.46）、（175.13 ± 13.41）和（224.77 ± 19.97）pg/ml,免疫治疗组和抑制剂组均明显高于哮喘组（t = 17.31,t = 11.71,P < 0.01）。哮喘组、免疫治疗组、抑制剂组和PBS组小鼠BALF中IL-5水平分别为（208.64 ± 11.55）、（106.87 ± 11.39）、（140.71 ± 14.58）和（90.15 ± 9.49）pg/ml,哮喘组的水平明显高于其他各组（F = 97.19,P < 0.01）。哮喘组和免疫治疗组BALF中IL-13水平分别为（308.37 ± 13.67）pg/ml和（175.66 ± 11.79）pg/ml,两者差异有统计学意义（P < 0.01）;抑制剂组小鼠的为（221.12 ± 21.08）pg/ml,明显低于哮喘组（t = 16.44,P < 0.01）;PBS组为（97.57 ± 18.38）pg/ml。免疫治疗组与哮喘组相比,小鼠肺部炎性症状均减轻,几乎无炎症细胞。抑制剂组小鼠的支气管周围也有嗜酸粒细胞增多症、上皮细胞脱落和支气管上皮细胞肥大,但较哮喘组要减轻许多。血清IgE抗体水平的检测结果显示,哮喘组、免疫治疗组、抑制剂组和PBS组分别为（31.97 ± 3.48）、（12.86 ± 2.22）、（18.43 ± 2.30）和（9.68 ± 1.27）IU/ml,免疫治疗组和抑制剂组均低于哮喘组（t = -7.77,P < 0.01）。IgG2a抗体水平的变化和IgE相反,哮喘组、免疫治疗组和PBS组分别为（26.94 ± 2.96）、（35.06 ± 2.57）和（10.31 ± 1.48）μg/ml,免疫治疗组高于哮喘组（t = 6.55,P < 0.01）。结论 ELISA检测结果表明IL-33/ST2信号通路在小鼠过敏性哮喘中发挥着重要的作用。

关键词: 粉尘螨, Der f 1蛋白, 过敏性哮喘, 白细胞介素-33

Abstract:

Objective To investigate the change and the role of interleukin-33 (IL-33) in mice with allergic asthma induced by Dermatophagoides farinae group 1 allergen (Der f 1). Methods Forty female BALB/c mice were randomized into four groups using a random number table method: asthma group (sensitized by Der f 1 allergen), SIT group (specific immunotherapy with Der f 1), inhibitor administration group and negative control group (PBS group) (n = 10 for each). All mice except the PBS group were intraperitoneally injected with Dermatophagoides farinae allergen extract containing 100 μg/ml Der f 1 on days 0, 7 and 14, and those in the inhibition group also received an intraperitoneal injection of inhibitor (soluble ST2) at the same time. From day 21, mice in the three groups were sensitized through aerosol inhalation of the extract (0.5 μg/ml for 30 min , once per day for consecutive days). Mice in the immunotherapy group began to receive an immunotherapy through intraperitoneal injection of 200 μl of Der f 1 protein solution (100 μg/ml) 0.5 h prior to aerosol inhalation, from day 25 on, while in the PBS group, PBS was used instead of Der f 1. Twenty-four hours after the final aerosol inhalation on day 27, all the mice were sacrificed to collect the bronchoalveolar lavage fluid (BALF) and eyeball blood. The total eosinophils in BALF were counted and pulmonary histopathological sections were prepared. ELISA was performed to measure the levels of cytokines IL-5, IL-13, IFN-γ and IL-33 in the BALF, as well as serum levels of IgE and IgG2a. Results All groups except for the PBS group displayed different degrees of asthma symptoms since day 21. From day 25, the asthma symptoms in the immunotherapy group began to show remission. The total numbers of BALF eosinophils in the immunotherapy group and the inhibitor group were (1.43 ± 0.14） × 10⁵/ml and (2.73 ± 0.33） × 10⁵/ml, respectively(t = 24.50, P < 0.01 between the two groups). The numbers of eosinophils in SIT group（1.43 ± 0.14） × 10⁵/ml and the inhibitor administration group (2.73 ± 0.33）× 10⁵/ml were both significantly lower than that in the asthma group（F = 129.72,P < 0.01）. ELISA results showed that the levels of IFN-γ in BALF in the asthma group, the SIT group, the inhibitor administration group and the negative control group were （83.06 ± 11.38）,（277.97 ± 22.46）,（175.13 ± 13.41）and（224.77 ± 19.97）pg/ml, respectively. The BALF IFN-γ levels in the SIT group and the inhibitor administration group were both significantly higher than that in the asthma group (t = 17.31, t = 11.71, P < 0.01). The levels of IL-5 in BALF in the asthma group, the SIT group, the inhibitor administration group and the negative control group were （208.64 ± 11.55）,（106.87 ± 11.39）,（140.71 ± 14.58）and（90.15 ± 9.49）pg/ml, respectively. The BALF IL-5 level in the asthma group was significantly higher than that in the other groups (F = 97.19, P < 0.01). There was a significant difference in the BALF IL-13 level between the asthma group [(308.37 ± 13.67) pg/ml] and the SIT group [(175.66 ± 11.79) pg/ml] (P < 0.01), and that in the inhibition group was significantly lower than that in the asthma group (t = 16.44, P < 0.01). The BALF IL-13 level in the PBS group was (97.57 ± 18.38) pg/ml. Compared with the asthma group, mice in the SIT group showed improved inflammation in the lungs. Although the inhibition group also showed eosinophilia, epithelial cell shedding and bronchial epithelial cells around the bronchus, the symptoms were much attenuated compared with the asthma group. Serum IgE levels in the asthma group, the SIT group, the inhibitor administration group and the PBS group were （31.97 ± 3.48）,（1 2.86 ± 2.22）,（1 8.43 ± 2.30）and（9.68 ± 1.27）IU/ml, respectively. The serum IgE levels in the SIT group and the inhibitor administration group were both significantly lower than that in the asthma group (t = -7.77, P < 0.01). In contrast, the IgG2a level in the SIT group [(35.06 ± 2.57) μg/ml] was significantly higher than that in the asthma group [(26.94 ± 2.96) μg/ml] (t = 6.55, P < 0.01). The IgG2a level in the PBS group was(10.31 ± 1.48) μg/ml. Conclusion The IL-33/ST2 signaling pathway may play a critical role in allergic asthma by ELISA.

Key words: Dermatophagoides farinae, Der f 1 protein, Allergic asthma, IL-33

中图分类号:

R384.4

柴强, 宋红玉, 李朝品. 白细胞介素-33在过敏性哮喘小鼠体内的变化及作用[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(2): 124-129.

Qiang CHAI, Hong-yu SONG, Chao-pin LI. The change and role of interleukin-33 in mouse allergic asthma[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2018, 36(2): 124-129.

图/表 2

参考文献 29

[1]	Salazar F, Ghaemmaghami AM.Allergen recognition by innate immune cells: critical role of dendritic and epithelial cells[J]. Front Immunol, 2013, 4: 356.
[2]	Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary[J]. Eur Respir J, 2008, 31(1): 143-178.
[3]	Yu J, Jang SO, Kim BJ, et al. The effects of lactobacillus rhamnosus on the prevention of asthma in a murine model[J]. Allergy Asthma Immunol Res, 2010, 2(3): 199-205.
[4]	朱万春, 诸葛洪祥. 粉螨性哮喘发病机制研究进展[J]. 环境与健康杂志, 2007, 24(3): 184-186.
[5]	Fernández-Caldas E, Puerta L, Caraballo L.Mites and allergy[J]. Chem Immunol Allergy, 2014, 100: 234-242.
[6]	Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J]. Immunity, 2005, 23(5): 479-490.
[7]	Hayakawa H, Hayakawa M, Kume A, et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation[J]. J Biol Chem, 2007, 282(36): 26369-26380.
[8]	Snelgrove RJ, Gregory LG, Peiró T, et al. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations[J]. J Allergy Clin Immunol, 2014, 134(3): 583-592.
[9]	O′Grady SM, Patil N, Melkamu T, et al. ATP release and Ca2+ signalling by human bronchial epithelial cells following alternaria aeroallergen exposure[J]. Physiol (Lond), 2013, 591(18): 4595-4609.
[10]	Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4[J]. J Immunol, 2008, 181(7): 4780-4790.
[11]	Kouzaki H, Iijima K, Kobayashi T, et al. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses[J]. J Immunol, 2011, 186(7): 4375-4387.
[12]	Louten J, Rankin AL, Li Y, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation[J]. Int Immunol, 2011, 23(5): 307-315.
[13]	Funakoshi-Tago M, Tago K, Hayakawa M, et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway[J], Cell Signal, 2008, 20(9): 1679-1686.
[14]	向莉, 付亚南, 王静, 等. 哮喘患儿家庭内尘螨变应原含量分布特征及其影响因素[J]. 中华临床免疫和变态反应杂志, 2013, 7(4): 314-321.
[15]	李朝品, 赵蓓蓓, 湛孝东. 屋尘螨1类变应原T细胞表位融合肽对过敏性哮喘小鼠的免疫治疗效果[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(3): 214-219.
[16]	Milian E, Diaz AM.Allergy to house dust mites and asthma[J]. P R Health Sci J, 2004, 23(1): 47-57.
[17]	Yu JM, Luo QH, Sun JL, et al. Diversity of house dust mite species in Xishuangbanna Dai, a tropical rainforest region in Southwest China[J]. Biomed Res Int, 2015.
[18]	李朝品, 沈兆鹏. 中国粉螨概论[M]. 北京: 科学出版社,2016: 520-523.
[19]	Vargas MH, Diaz-Mejia GS, Furuya ME, et al. Trends of asthma in Mexico: an 11-year analysis in a nationwide institution[J]. Chest, 2004, 125(6): 1993-1997.
[20]	姜玉新, 尹康, 靳文杰, 等. 粉尘螨变应原Der f 1 mRNA对小鼠特异性免疫治疗的实验研究[J]. 中国寄生虫学与寄生虫病杂志, 2014, 32(4): 268-273.
[21]	Barnes PJ.New therapies for asthma: is there any progress[J]. Trends Pharmacol Sci, 2010, 31(7): 335-343.
[22]	Ji NF, Xie YC, Zhang MS, et al. Ligustrazine corrects Th1/Th2 and Treg/Th17 imbalance in a mouse asthma model[J]. Int Immunopharmacol, 2014, 21(1): 76-81.
[23]	Agache I, Akdis C, Jutel M, et al. Untangling asthma phenotypes and endotypes[J]. Allergy, 2012, 67(7): 835-846.
[24]	Li M, Li Y, Liu X, et al. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice[J]. J Neuroimmunol, 2012, 247(1-2): 25-31.
[25]	姜玉新, 尹康, 靳文杰, 等. 粉尘螨变应原Der f 1 mRNA对小鼠特异性免疫治疗的实验研究[J]. 中国寄生虫学与寄生虫病杂志, 2014, 32(4): 268-273.
[26]	Kurokawa M, Matsukura S, Kawaguchi M, et al. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts[J]. Int Arch Allergy Immunol, 2011, 155(Suppl 1): 12-20.
[27]	Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J]. J Clin Invest, 2007, 117(6): 1538-1549.
[28]	Imai Y, Yasuda K, Sakaguchi Y, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice[J]. Proc Natl Acad Sci USA, 2013, 110(34): 13921-13926.
[29]	Lee HY, Rhee CK, Kang JY, et al. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma[J]. Exp Lung Res, 2014, 40(2): 66-76.

组别 Group	嗜酸粒细胞 Eosinophils （×10⁵/ml）	γ干扰素 IFN-γ	白细胞介素-5 IL-5	白细胞介素-13 IL-13
哮喘组 Asthma group	4.41 ± 0.36	83.06 ± 11.38	208.64 ± 11.55^d	308.37 ± 13.67
免疫治疗组 Immunotherapy group	1.43 ± 0.14	277.97 ± 22.46^c	106.87 ± 11.39	175.66 ± 11.79^e
抑制剂组 Inhibitor group	2.73 ± 0.33^b	175.13 ±13.41^c	140.71 ± 14.58	221.12 ± 21.08^e
PBS组 PBS group	0.37 ± 0.08^a	224.77 ± 19.97	90.15 ± 9.49	97.57 ± 18.38